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Improved radiopharmaceuticals for imaging cerebral acetylcholinesterase (AChE) are 
needed for the diagnosis of Alzheimer’s disease (AD). Thus, 11C-labeled 
(−)-galanthamine and its enantiomers were synthesized as novel agents for imaging the 
localization and activity of AChE by positron emission tomography (PET). C-11 was 
incorporated into (−)- and (+)-[11C]galanthamine by N-methylation of norgalanthamines 
with [
11
C]methyl triflate. Simple accumulation of 
11
C in the brain was measured in an in 
vivo biodistribution study using mice, whilst donepezil was used as a blocking agent in 
analogous in vivo blocking studies. In vitro autoradiography of rat brain tissue was 
performed to investigate the distribution of (−)-[11C]galanthamine, and confirmed the 
results of PET studies in mice. The radiochemical yields of N-methylation of (−)- and 
(+)-norgalanthamines were 13.7 and 14.4%, respectively. The highest level of 
accumulation of 
11
C in the brains of mice was observed at 10 min after administration 
(2.1% ID/g). Intravenous pretreatment with donepezil resulted in a 30% decrease in 
accumulation of (−)-[11C]galanthamine in the striatum; however, levels in the 
4 
cerebellum were unchanged. In contrast, use of (+)-[
11
C]galanthamine led to 
accumulation of radioactivity in the striatum equal to that in the cerebellum, and these 
levels were unaffected by pretreatment with donepezil. In in vitro autoradiography of 
regional radioactive signals of brain sections showed that pretreatment with either 
(−)-galanthamine or donepezil blocked the binding of (−)-[11C]galanthamine to the 
striatum, while sagittal PET imaging revealed accumulation of (−)-[11C]galanthamine in 
the brain. These results indicate that (−)-[11C]galanthamine showed specific binding to 
AChE, whereas (+)-[
11
C]-galanthamine accumulated in brain tissue by non-specific 
binding. Thus, optically pure (−)-[11C]galanthamine could be a useful PET tracer for 
imaging cerebral AChE. 
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Sagittal PET image of (−)-[11C]galanthamine in the ddY mouse.  
5 
1. Introduction 
The function of the brain cholinergic system, where acetylcholine (ACh), 
acetylcholinesterase (AChE) and choline acetyltransferase (ChAT) act to control the 
potential of nerve cells, is crucial to memory, learning, and recognition. Decreases in the 
activities of AChE and ChAT have been observed in the brains of patients suffering 
from Alzheimer's disease (AD), while increased activity of AChE in some regions, for 
example the hippocampus and striatum, has been correlated with cognitive decline in 
AD patients.
1
 Thus, some AChE inhibitors have been approved for treating mild to 
moderate AD. 
Because noninvasive methods for visualizing AChE levels would be useful for 
monitoring the treatment and progression of AD, studies have been performed using the 











C]donepezil, have been developed as 
radio-tracers specifically binding AChE, and their utility has been evaluated in PET 
studies.
5−7
 Besides donepezil and tacrine, (−)-galanthamine, an alkaloid isolated from 
6 
Galanthus woronowii and Lycoris radiata, was also developed as a treatment for AD 
because it showed several biological activities, including allosteric modulation of the 
nicotinic acetylcholine receptor, and inhibition of AChE.
8
 Meanwhile, we have reported 
a novel synthetic route to (±)-galanthamine and (−)-galanthamine which avoids the use 
of narwedine (which causes a fatal allergic response in some workers.
9,10
) as an 
intermediate.  
Thus, we examined the potential of (−)- and (+)-[11C]galanthamine (Figure 1) 
as PET probes in in vitro and in vivo experiments. 
 
2. Materials and methods 




C NMR spectra were recorded on a JNM-AL400 spectrometer (JEOL, Tokyo, 
Japan) with CDCl3 as a solvent and tetramethylsilane (0.00) as an internal standard. 
Mass spectra (MS) were obtained using a JMS-HX/HX110 A spectrometer (JEOL, 
Tokyo, Japan). Specific rotations were measured on a p-1020 digital polarimeter (Jasco, 
7 
Tokyo, Japan). Silica gel 60N (63–210 μm, Kanto Chemical, Tokyo, Japan) was used 
for open column chromatography. Silica gel 60 F-254 plates (Merck, Darmstadt, 
Germany) were used for thin-layer chromatography (TLC). Preparative TLC was 
performed on silica gel 60 F-254 plates (0.25 mm, Merck) or silica gel 60 F-254 plates 
(0.5 mm, Merck). All chemicals used were of reagent grade.  
 
2.2. Animal experiments 
Experiments were performed on seven-week-old male ddY mice (20–25 g) and 
nine-week-old male Wistar rats (300 g) in accordance with the institutional guidelines, 





Trifluoromethanesulfonic anhydride (1.88 mL, 11.1 mmol) was added to a 
8 
solution of (±)-3-hydroxy-N-trifluoroacetyl-N-nornarwedine (2) (665 mg, 1.7 mmol) in 
pyridine (10 mL) and the reaction mixture was stirred for 75 min at 0°C. Methanol (4 
mL) was then added to the mixture, and the organic solvent then removed by 
evaporation under reduced pressure. The residue was extracted with ethyl acetate, 
washed with an aqueous solution of sodium bicarbonate (5%), and then brine, dried 
over magnesium sulfate, and concentrated to dryness in vacuo. The residue was purified 
by silica gel column chromatography (n-hexane:acetone = 1:1) to afford compound 3 as 
colorless crystals (800 mg, 91%). 
1
H NMR (400 MHz, CDCl3)  2.11–2.22 (m, 2H), 2.44 (ddt, 
J = 1.9, 3.5, 14.1 Hz, 1H), 2.79 (dd, J = 3.7, 17.8 Hz, 1H), 2.81 (dd, J = 3.7, 17.9 Hz, 1H), 3.16 (d, 
J = 17.9 Hz, 1H), 3.17 (d, J = 17.9 Hz, 1H), 3.37 (br t, J = 13.7 Hz, 0.5H), 3.74 (br t, J = 13.7 Hz, 
0.5H), 4.00 (s, 1.5H), 4.01 (s, 1.5H), 4.13 (d, J = 15.3 Hz, A part of AB type, 0.5H), 4.37 (d, J = 
16.1 Hz, 0.5H), 4.55 (d, J = 16.8 Hz, A’ part of A’B’ type, 0.5H), 4.77 (d, J = 13.7 Hz, 0.5H), 
4.83–4.86 (m, 1H), 4.86 (d, J = 16.8 Hz, B part of AB type, 1H), 5.24 (d, J = 15.4 Hz, B’ part of 
A’B’ type, 0.5H), 6.14 (d, J = 10.3 Hz, 0.5H), 6.17 (d, J = 9.5 Hz, 0.5H), 6.65 (s, 0.5H), 6.79 (d, J 
= 10.6 Hz, 0.5H), 6.80 (d, J = 10.6 Hz, 0.5H), 6.82 (s, 0.5H), 6.86 (d, J =10.6 Hz, 0.5H), 6.87 (d, J 
9 
= 10.6 Hz, 0.5H). 
13
C NMR (100 MHz, CDCl3)  34.85, 37.43, 37.48, 46.90, 47.14 (2C), 48.78, 
48.83, 51.76, 52.61, 60.99, 61.01, 89.04, 89.16, 115.03, 115.19, 116.09, 117.41 (2C), 117.92, 
118.05, 120.61 (2C), 128.04, 128.29, 128.84, 129.03, 131.28, 131.31, 137.71, 137.76, 141.20, 
161.27, 141.80, 142.27, 150.65, 150.81, 156.46, 156.66, 156.80, 157.03, 193.44, 193.50. mp 
109–111°C. Anal. Calcd for C19H15F6NO7S:C, 44.28; H, 2.93; N, 2.72. Found for C19H15F6NO7S: 
C, 44.17; H, 3.02; N, 2.71. HRMS (FAB+) m/z: 515.0469 (Calcd for C19H15F6NO7S:515.0473). 
 
(±)-N-Trifluoroacetyl-N-nornarwedine (4) 
Formic acid (99%, 570 L, 3.52 mmol × 4) was added to a mixture of 
compound 3 (1.95 g; 3.52 mmol), palladium acetate (18.9 mg, 3.52 mmol × 0.02), 
1,1′-bis(diphenylphosphino)ferrocene (dppf) (85 mg, 3.52 mmol × 0.04), and 
triethylamine (3.3 mL, 3.52 mmol × 6) in DMF (18 mL) at 0°C. The reaction mixture 
was stirred for 1 h at 60°C and then quenched by pouring into ice-water. The mixture 
was then filtered and the residue remaining on the filter paper was dissolved in ethyl 
acetate. The organic layer was washed with brine, dried over magnesium sulfate, and 
10 
concentrated to dryness in vacuo. The residue was purified by silica gel column 
chromatography (n-hexane:acetone = 1:1) and was further recrystallized from methanol 
to afford compound 4 as colorless crystals (1.25 g, 97%).
1 
H NMR (400 MHz, CDCl3)  
2.09–2.20 (m, 2H), 2.22 (ddt, J = 1.8, 3.7, 13.9 Hz, 0.5H), 2.76 (dd, J = 3.7, 14.2 Hz, 0.5H), 2.78 
(dd, J = 3.7, 14.1 Hz, 0.5H), 3.21 (d, J = 14.1 Hz, 1H), 3.36 (m, 0.5H), 3.74 (br t, J = 13.6 Hz, 
0.5H), 3.85 (s, 1.5H), 3.86 (s, 1.5H), 4.15 (d, J = 15.1 Hz, 0.5H), 4.36 (br d, J = 15.8 Hz, 0.5H), 
4.56 (d, J = 16.7 Hz, 0.5H), 4.73–4.76 (m, 1H), 4.77 (d, J = 16 Hz, 0.5H), 4.91 (br d, J = 16.7 Hz, 
0.5H), 5.31 (d, J = 15.1 Hz, 0.5H), 6.08 (d, J = 10.4 Hz, 0.5H), 6.11 (d, J = 10.4 Hz, 0.5H), 6.75 (d, 
J = 8.2 Hz, 0.5H), 6.75 (s, 1H), 6.82 (dd, J = 2.2, 10.4 Hz, 0.5H), 6.89 (dd, J = 2.2, 10.4 Hz, 0.5H), 
6.90 (d, J = 8.2 Hz, 0.5H). 
13
C NMR (100 MHz, CDCl3) : 35.18, 37.44, 37.50, 38.14, 47.08, 
47.26, 47.29, 49.14, 49.19, 52.36, 53.22, 56.40, 56.41, 88.00, 88.12, 112.49, 115.18, 115.31, 
118.05, 118.17, 120.91, 121.54, 122.72, 126.46, 126.92, 128.27, 128.45, 129.89, 142.53, 142.53, 
142.95, 145.21, 145.26, 147.94, 148.07, 156.34, 156.70, 157.07, 193.99, 194.03. mp 164–165°C. 
Anal. Calcd for C18H16F3NO4: C, 58.86; H, 4.39; N, 3.81. Found for C18H16F3NO4: C, 59.13; H, 




An aqueous solution of sodium hydroxide (2 M, 9 mL) was added to a solution 
of compound 4 (1.3 g, 3.54 mmol) in methanol (80 mL), and the mixture was stirred 
for 40 min at room temperature. After the reaction, the organic solvent in the mixture 
was removed in vacuo. The remaining residue was diluted with a saturated aqueous 
solution of ammonium chloride, and this mixture was extracted with chloroform. The 
organic layer was concentrated to dryness in vacuo, and the residue was purified by 
silica gel column chromatography (chloroform:methanol = 1:1) to afford compound 5 
as colorless crystals (940 mg, 98%). 
1
H NMR (400 MHz, CDCl3)  1.93 (dt, J = 3.4, 13.6, 
1H), 2.12 (ddd, J = 1.8, 3.6, 13.6 Hz, 1H), 2.75 (dd, J = 3.7, 17.7 Hz, 1H), 3.16 (ddd, J = 0.9, 2.4, 
17.7 Hz, 1H), 3.21 (dt, J = 1.9, 14.7, 1H), 3.45 (dt, J = 3.5, 14.6 Hz, 1H), 3.84 (s, 3H), 4.02 (d, J 
= 15.7 Hz, A part of AB type, 1H), 4.05 (d, J = 15.7 Hz, B part of AB type, 1H), 4.73–4.75 (m, 
1H), 6.05 (dd, J = 0.5, 10.4 Hz, 1H), 6.65 (d, J = 8.2 Hz, A part of AB type, 1H), 6.68 (d, J = 8.2 
Hz, B part of AB type, 1H), 6.94 (dd, J = 8.2, 10.4 Hz, 1H). 
13
C NMR (100 MHz, CDCl3)   
12 
37.63, 39.93, 47.75, 49.90, 54.38, 56.39, 88.27, 112.04, 121.01, 127.44, 130.98, 133.65, 144.26, 
144.94, 147.73, 194.76. Mp.175–176°C. Anal. Calcd for C16H17NO3: C, 70.83; H, 6.32; N, 5.16. 
Found for C16H17NO3: C, 70.56; H, 6.14; N, 5.25. HRMS (FAB+) m/z: 272.1283 (Calcd for 
C16H18NO3: 272.1287). 
 
(±)-Norgalanthamine (6)  
A solution of lithium tri-sec-butylborohydride (L-selectride
®
) in THF (1M, 
12.5 mL) was added to a solution of compound 5 (925 mg, 3.4 mmol) in THF (50 mL) 
at −78°C, and the resulting mixture was stirred at this temperature for 2 h. Acetone (3 
mL) was then added to quench the reaction, and organic solvents in the mixture were 
then removed in vacuo. Methanol (25 mL) was added to the residue to give a precipitate, 
which was collected by filtration. Recrystallization of this precipitate from methanol 
gave (±)-norgalanthamine as colorless crystals (780 mg, 84%). 
1
H NMR (400 MHz, 
CD3OD)  2.07–2.11 (m, 2H), 2.18 (ddd, J = 3.1, 5.3, 15.8 Hz, 1H), 2.51 (d, J = 15.8 Hz, 1H), 
3.62–3.66 (m, 2H), 3.83 (s, 3H), 4.20 (brt, J = 4.8 Hz, 1H), 4.34 (d, J = 15.0 Hz, A part of AB type, 
13 
1H), 4.54 (d, J = 15.0 Hz, B part of AB type, 1H), 4.63 (dt, J = 1.3, 3.3 Hz, 1H), 6.02 (ddd, J = 1.0, 
4.9, 10.3 Hz, 1H), 6.15 (dt, J = 1.3, 10.3 Hz, 1H), 6.83 (d, J = 8.2 Hz, A part of AB type, 1H), 6.85 
(d, J = 8.2 Hz, B part of AB type, 1H). 
13
C NMR (100 MHz, CD3OD)  32.30, 36.77, 47.47, 
49.81, 52.58, 57.52, 62.93, 89.43, 114.47, 123.80, 124.41, 127.84, 130.88, 135.06, 147.94, 149.32. 
mp 235–236°C. Anal. Calcd for C16H19NO3: C, 70.31; H, 7.01; N, 5.12; O, 17.56. Found for 




Method A. Sodium cyanoborohydride (20 mg, 0.3 mmol) was added to a solution of 
(±)-norgalanthamine (27 mg, 0.1 mmol) and 37% formaldehyde (100 µL) in acetic acid 
(800 µL), and the mixture was stirred for 5 min at room temperature. After this time, the 
mixture was concentrated to dryness in vacuo. The residue was diluted with an aqueous 
solution of sodium bicarbonate (5%), and this resulting mixture extracted with 
chloroform. The organic layer was washed with brine, dried over sodium sulfate, and 
14 
concentrated to dryness in vacuo. The residue was purified by silica gel column 
chromatography (chloroform:methanol = 5:1) to afford (±)-galanthamine as colorless 
crystals (25 mg, 92%). 
Method B. Methyl triflate (227 µL, 2.0 mmol) was added to a solution of 
(±)-norgalanthamine (28 mg, 0.1 mmol) and cesium carbonate (665 mg, 2.0 mmol) in 
DMSO (1.5 mL) in a sealable tube. The tube was sealed, and then stirred for 5 min at 
170°C. After this time, the mixture was neutralized with sodium bicarbonate and 
extracted with chloroform. The organic layer was washed three times with brine, dried 
over sodium sulfate, and concentrated to dryness in vacuo. The residue was purified by 
silica gel column chromatography (chloroform:methanol = 5:1) to afford 
(±)-galanthamine as colorless crystals (10 mg, 33%). 
1
H NMR (400 MHz, CDCl3)  1.58 
(ddd, J = 1.8, 4.0, 13.7 Hz, 1H), 2.01 (ddd, J = 1.8, 3.5, 15.7 Hz, 1H), 2.09 (dt, J = 3.1, 13.4 Hz, 
1H), 2.42 (s, 3H), 2.44 (br s, OH), 2.69 (ddd, J = 1.5, 3.3, 15.7 Hz, 1H), 3.05 (br d, J = 13.7 Hz, 
1H), 3.27 (dt, J = 1.7, 13.7 Hz, 1H), 3.69 (dd, J = 1.1, 15.2 Hz, A part of AB type, 1H), 3.83 (s, 
3H), 4.09 (d, J = 15.2 Hz, B part of AB type, 1H), 4.61 (br, 1H), 6.00 (ddd, J = 1.2, 4.0, 10.2 Hz, 
15 
1H), 6.07 (d, J = 1.2, 10.2 Hz, B part of AB type, 1H), 6.62 (d, J = 8.2 Hz, A part of AB type, 1H), 
6.66 (d, J = 8.2 Hz, B part of AB type, 1H). 
13
C NMR (100 MHz, CDCl3) : 30.29, 34.20, 42.52, 
48.57, 54.21, 56.24, 61.01, 62.44, 89.09, 111.50, 122.38, 127.94, 127.23, 129.77, 133.43, 144.43, 
146.15. mp 122–123°C. Anal. Calcd for C17H21NO3: C, 71.06; H, 7.37; N, 4.87. Found for 
C17H21NO3: C, 70.88; H, 7.23; N, 4.99. HRMS (FAB+) m/z: 288.1605 (Calcd for C17H22NO3 
288.1600). 
 
(−)- and (+)-Galanthamine 
A solution of (+)- and (−)-norgalanthamine (0.46 mg), cesium carbonate (12.06 
mg), and methyl triflate (4 L) in DMSO (50 L) was added to a sealable tube, which 
was then sealed, and the reaction mixture was stirred for 5 min at 170°C. The reaction 
mixture was analyzed using an HPLC system equipped with a Chiralcel IC column (4.6 
× 250 mm, Daicel, Tokyo, Japan), and was separated using a mix of solvents (methyl 
t-butyl ether:ethanol:diethylamine 95:5:0.1) on the same system, at a flow rate of 1.0 
mL/min. The retention times of (+)- and (−)-galanthamine, which were detected by UV 
16 
absorption at 254 nm, were 12.7 min ([]D
18
 = +141.62° (c 0.68, ethanol)) and 14.4 min 
([]D
18
 = −125.99° (c 0.66, ethanol)), respectively . 
 
2.4. Optical resolution 
The optical resolution of (±)-norgalanthamine was performed on an HPLC 
system equipped with a Chiralcel IC column (10 × 250 mm, Daicel) with a mobile 
phase consisting of n-hexane, ethanol, and diethylamine (70:30:0.1), which was run at a 
flow rate of 5.0 mL/min at 30°C. The elution of the two enantiomers was detected by 
UV absorption at 254 nm, with (+)- and (−)-norgalanthamine obtained as colorless 





 (c 0.29, CHCl3)) and 38.7 min ([]D
25






C was prepared by a 
14
N(p, )11C reaction using a cyclotron system (CYPRIS 









CO2 dissolved in THF was reduced to [
11
C]methanol with lithium 
aluminum hydride. [
11
C]Methanol was reacted with hydrogen iodide to produce 
[
11
C]methyl iodide, which was then converted to [
11
C]methyl triflate by passage through 
a silver triflate column. [
11
C]Methyl triflate was reacted with either (−)-norgalanthamine 
or (+)-norgalanthamine (2 mg/mL, 160 µL) in DMSO, with the mixture being vortexed 
and heated at 170°C for 5 min. The reaction mixture was purified using an HPLC 
system equipped with a Cosmosil 5C18-MS-II column (10 × 250 mm, Nacalai, Kyoto, 
Japan) using a mobile phase consisting of water, acetonitrile, and diisopropylamine 
(77:23:0.2) at a flow rate of 4 mL/min. The desired product was detected by UV 
absorption at 254 nm. The retention time of (−)- and (+)-[11C]galanthamine was 13.9 
min, while that of (−)- and (+)-norgalanthamine was 7.5 min. The radiochemical purity 




2.6. Measurement of AChE Activity 
      The inhibitory activities of (−)- and (+)-galanthamine against AChE were 
measured using a modified version of the colorimetric method of Ellman.
13
 Thus, 2 µL 
of a 10-mM solution of inhibitor in 0.1 M phosphate buffer (pH 8) was mixed with 190 
µL of AChE solution (extracted from the brain tissue of a 9-week-old rat) in each well 
of a 96-well titer plate. After the incubation of the titer plate for 30 min at 37°C, 600 µL 
of 10-mM 5,5’-dithiobis-(2-nitrobenzoic acid) (DTNB), 100 µL of 150-mM 
acetylthiocholine iodide and 100 µL of buffer were successively added. Changes in UV 
absorbance of the reaction mixture were then measured at 2 min intervals in a 96-well 
plate reader at 415 nm, three times, consecutively. Percentage inhibition was calculated 
by comparison with that for the control (phosphate buffer).  
Inhibition (%) = (1 – Ainhibitor/Acontrol) × 100 
(−)-Galanthamine hydrobromide from Lycoris sp. (Sigma) served as a positive 
indicator for measuring the inhibition of the synthesized (−)- and (+)-galanthamines. 
 
19 
2.7. Biodistribution studies  
Either (−)-[11C]galanthamine or (+)-[11C]galanthamine (3.7 MBq each) was 
administered to seven-week-old male ddY mice. Five animals were then sacrificed by 
exsanguination at time-points of 2, 5, 15, 30, and 60 min post-administration. The 
excised blood and brain (or brain tissues, i.e., striatum and cerebellum) were weighed, 
and the radioactivities of the organs were measured using an auto-well gamma counter 
(Cobra Auto-Gamma Counter 5003, Packard, Meriden, CT, USA). Radioactivity levels 
of the organs are expressed as the percentage of injected dose per gram of tissue (% 
ID/g). 
As in in vivo blocking studies, mice were pre-treated with donepezil (1.2, 2.3, 
and 4.6 mg/kg) via tail-vein injection 30 min before administration of (−)- or 
(+)-[
11
C]galanthamine. Ten minutes after administration of radioactive 
[
11
C]galanthamine, the accumulation of radioactivity to the brain tissue was measured. 
 
2.8. In vitro autoradiographic experiments 
20 
In vitro autoradiography was performed on 20-µm coronal brain sections from 
male Wistar rats. The sections were thaw-mounted onto precleaned silane-coated slides, 
and incubated with (−)-[11C]galanthamine (2.2 q/200 µL) in a binding buffer for 30 
min at 4°C. After washing with ice-cold binding buffer and ice-cold water, the slides 
were placed on Fuji imaging plates (BAS-SR, Fujifilm Photo Film, Tokyo, Japan) for 6 
h, together with calibrated 
11
C-labeled external standards. 
As in in vitro blocking experiments, brain tissues were incubated with 
(−)-[11C]galanthamine in the presence of 10 mM (−)-galanthamine or 20 µM donepezil. 
The images were analyzed using a bio-imaging analyzer (BAS5000, Fujifilm Photo 
Film, Tokyo, Japan) and Image Gauge software (Fujifilm Photo Film).  
 
2.9. PET studies 
PET studies were performed using a GE Healthcare eXplore VISTA PET 
camera (GE Healthcare, Little Chalfont, UK). A seven-week-old male ddY mouse 
(20–25 g) was anesthetized (1.5% isoflurane) and (−)-[11C]galanthamine (74 MBq, in 
21 
0.2 mL isotonic saline) was injected via the tail vein. Emission data from the animal 
were then collected for 10–30 min. The images were reconstructed using a 2-D 
ordered-set expectation-maximization algorithm. 
 
2.10. Statistical analysis 
Data are expressed as means ± SD. The statistical significance of differences 




3.1. Synthesis of galanthamine 
The synthetic routes to (±)-galanthamine (1) and (±)-norgalanthamine (6) are 
shown in Scheme 1. (±)-3-Hydroxy-N-trifluoroacetyl-N-nornarwedine (2)
9,10
 was 
converted to triflate 3 by a conventional method, and subsequent reduction of 3 with 
formic acid in the presence of palladium acetate and dppf gave narwedine derivative 4. 
22 
The trifluoroacetamide group of 4 was cleaved by hydrolysis with methanolic sodium 
hydroxide to afford the amine 5. Subsequent diastereoselective reduction of 5 with 
L-selectride
®
 gave (±)-norgalanthamine (6) in good yield (84%). An alternative 
N-methylation of 5 was attempted using methyl iodide or methyl triflate as the 
methylating agent. However, the former conditions gave no product, while the latter 
conditions provided only a low yield of (±)-galanthamine (33%). The overall yield of 
(±)-galanthamine from 2 was 25%. 
(±)-Norgalanthamine (6) could be separated into optically pure (+)- and (−)-6 
using an HPLC system equipped with a chiral column. 
 
3.2. Radiolabeling of (−)- and (+)-[11C]galanthamine 
Both (−)- and (+)-[11C]galanthamine were synthesized according to the route 
shown in Scheme 2. The radiochemical yields of (−)- and (+)-[11C]galanthamine from 
(−)- and (+)-6 were 13.7 and 14.4%, respectively, and their radiochemical purities were 
>99%. No significant difference in [
11
C]-labeling efficiency of the enantiomers was 
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observed (Scheme 2). 
 
3.3. Measurement of AChE Activity 
The AChE-inhibitory activities of ()- and (+)-galanthamine are shown in Table 
1. Percentage inhibition was measured by the Ellman method. Naturally occurring and 
synthesized ()-galanthamine showed similar potent inhibition of AChE (95 ± 1.0% and 
94 ± 2.7%, respectively), while (+)-galanthamine exhibited only weak inhibition (10 ± 
4.4%). 
 
3.4. Biodistribution studies 
The distributions of (−)- and (+)-[11C]galanthamine are summarized in Figure 2. 
Both (−)- and (+)-[11C]galanthamine rapidly penetrated the brain. The highest levels of 
radioactive galanthamine in the brain were observed at 10 min post-injection (2.1% 
ID/g for both compounds), at which point the brain:blood ratios of the compound were 
~1.5:1.0. 
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The regional distribution of radioactivity in the mouse brain is shown in Figure 
3. Accumulation of (−)-[11C]galanthamine was greater in the striatum (2.1% ID/g, 
AChE-rich region) than in the cerebellum (1.7% ID/g, an AChE-poor region). In 
contrast, there was no difference in accumulation of (+)-[
11
C]galanthamine in these 
region (i.e., 1.5% ID/g for the striatum; 1.5% ID/g for the cerebellum).  
Pretreatment with donepezil had no effect on striatal accumulation of 
(+)-[
11
C]galanthamine, but did lead to a significant decrease in accumulation of 
(−)-[11C]galanthamine (i.e. dose-dependently, to the basal level (1.3% ID/g, 4.6 
mg/kg)). 
 
3.5. In vitro autoradiographic experiments  
In vitro autoradiographic analyses were performed (Figure 4) to investigate the 
regional distribution of (−)-[11C]galanthamine in the brain in more detail. The 
radioactivity level was the highest in the striatum (Fig. 4b), consistent with the 
distribution of AChE observed in immunostaining (Fig. 4a). Furthermore, the effects of 
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(−)-galanthamine (10 mM) (Fig. 4c) and donepezil (20 M) (Fig. 4d) on the striatal 
uptake of (−)-[11C]galanthamine were studied. Striatal accumulation of 
(−)-[11C]galanthamine significantly decreased in the presence of galanthamine or 
donepezil (Fig. 4e). 
 
3.6. PET studies 
Sagittal PET imaging of mouse brain revealed the localization of 
(−)-[11C]galanthamine in the striatum (Fig. 5), which coincided with the localization of 
AChE in the brain as determined by immunostaining and in vitro autoradiography. 
 
4. Discussion 
Because the half-life time of 
11
C is very short (~20 min), the 
11
C-containing 
moiety should be incorporated in the final step of preparation of the target compound. 
Accordingly, we developed a synthetic pathway using a facile N-methylation of 
norgalanthamine with [
11
C]methyl triflate. The required (±)-norgalanthamine precursor 
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was synthesized efficiently in good overall yield (Scheme 1), and it was important to 
conduct the N-Methylation of (±)-norgalanthamine to (±)-galanthamine within a short 
time-period. An alternative route to 6 via reductive methylation of 5 was not explored, 
due to the difficulty in preparing and handling the required [
11
C]formaldehyde. 
The synthesized (−)-norgalanthamine [(−)-6] was identified by comparing its 
spectroscopic and specific rotation data with analogous data of an authentic sample of 
(−)-614 obtained by chiral HPLC resolution of (±)-norgalanthamine. Chiral HPLC also 
showed that methylation of (−)-6 produced only (−)-galanthamine, meaning that (−)- 
and (+)-[
11
C]galanthamine were obtained from their respective precursors with 
radiochemical yields of 13.7 and 14.4%, respectively, and radiochemical purities >99%. 
In vitro experiments indicated that (−)-galanthamine had inhibitory activity 
against AChE comparable with the activity of commercially available (−)-galanthamine 
hydrobromide, while (+)-galanthamine was only weakly active. 
In the study of the biodistribution of (−)- and (+)-[11C]galanthamine in normal 
mice, the total uptake amount of each isomer in brain was almost the same, which 
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meant that the chirality of galanthamine had no effect on its ability to penetrate the 
blood–brain barrier.  
In regional distribution studies in normal mouse brains, accumulation of 
(−)-[11C]galanthamine was greater in the striatum than in the cerebellum. It is 
considered that these differences reflect the distribution of AChE in brain tissue.
7,15
 
Meanwhile, the difference in the accumulation of (+)-[
11
C]galanthamine in these regions 
was not significant. Accumulation of (−)-[11C]galanthamine significantly decreased 
after in vivo donepezil pretreatment; however, accumulation of (+)-[
11
C]galanthamine 
was unaffected. Incomplete blockade of striatal (−)-[11C]galanthamine accumulation by 
pre-injection of a fatal dose of donepezil (4.6 mg/kg) may represent nonspecific binding 
to brain tissues.  
The slightly higher lipophilicity of (−)- and (+)-[11C]galanthamine (log P = 
1.41, as calculated with ChemBioDraw Ultra 12.0) may explain the significant 
nonspecific accumulation of these compounds in the cerebellum, despite the low levels 
of AChE in this area of the brain. 
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 In addition, it is reported that (−)-galanthamine not only inhibits AChE, but 
also binds to α7 or α4β2 nicotinic acetylcholine receptors (AChRs), and allosterically 
stimulates the pharmacological action of acetylcholine.
16,17
 Because donepezil possesses 
affinity for muscarinic M1 AChRs,
18
 but not for nicotinic AChRs, striatal radioactivity 
after the donepezil-blockade can include the binding of (−)-[11C]galanthamine to 
nicotinic AChRs. 
Autoradiographic analyses demonstrated that (−)-[11C]galanthamine, as 
detected by immunostaining, accumulated within AChE-abundant regions of the brain, 
and its accumulation was significantly decreased by pre-treatment of animals with 
donepezil. These results indicate that (−)-[11C]galanthamine bound to AChE. The fact 
that both (−)-galanthamine and donepezil did not completely block the accumulation of 
(−)-[11C]galanthamine in the striatum can be explained by the lipophilicity of the latter, 
as discussed above. 
PET imaging of mice injected with [
11
C]galanthamine showed greater 
localization of radioactivity in the striatum than in the cerebellum. This is considered to 
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support the data of the in vivo biodistribution study and the in vitro autoradiographic 
experiment. The results indicate that (−)-[11C]galanthamine satisfies the basic 
requirements for a radiotracer, and that it could be a potential PET tracer for AChE 
expression.  
Our PET analyses did not include blocking studies using donepezil or other 
ligands targeting the brain cholinergic system; however, (−)-galanthamine is a 
therapeutic drug in clinical use for AD patients and the pharmacologic binding site is 
well defined. The targets of (−)-galanthamine are: 1) AChE and 2) nicotinic AChR (as 
an allosteric potentiating ligand). From this point of view, experiments to demonstrate 
how AChE concentration actually contributes to brain PET images should be studied 
using AD model animals. Further comparison with other binding-type AChE PET 




 may also provide new insights into AD pathology. 
Relative potency of AChE inhibition (Ki) for donepezil was 3- to 15-fold higher than 
that for galantamine,
19
 suggesting that (−)-[11C]galanthamine itself has lower affinity for 
AChE compared with [
11
C]donepezil. The low affinity is unfavorable for AChE 
30 
imaging by (−)-[11C]galanthamine; however, different images derived from the different 
binding properties of those two tracers, i.e., [
11
C]donepezil and (−)-[11C]galanthamine, 
could shed new light on the pathogenesis and progression of AD. 
 
5. Conclusion 
We have devised a simple synthetic method for generating (−)- and 
(+)-[
11
C]galanthamine, and evaluated their potential as PET tracers for imaging the level 
and activity of AChE in murine brain tissue. The results indicate that 
(−)-[11C]galanthamine shows radioactive signals which include specific binding to 
AChE, whereas (+)-[
11
C]galanthamine only shows radioactive signals representative of 
non-specific binding. This means that signals derived solely from (−)-[11C]galanthamine 
can be used to indicate the amount of AChE.  
(−)-[11C]Galanthamine thus satisfies the basic requirements for a potential PET 
tracer for imaging the amount and activity of AChE. The characteristics of 
(+)-[
11
C]galanthamine may also provide useful information for the development of 
31 
practical radiopharmaceuticals as PET tracers for cerebral AChE imaging. 
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Fig. 2. Brain and blood levels of (−)-[11C]galanthamine (A) and (+)-[11C]galanthamine 
(B) in ddY mice. Values representing % injected dose/gram tissue are means ± s.d. (n = 
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Fig. 3. Effect of different dosages of donepezil on the uptake of (−)-[11C]galanthamine 
(A) and (+)-[11C]galanthamine (B) in two brain regions of mice. Both (−)- and (+)-
[11C]galanthamine were administered intravenously (i.v.), 30 min after i.v. donepezil 
treatment [where * p < 0.05; ** p < 0.01 (vs. control)]. 
Figure 4. (a) (b) (c) (d) 















































Fig. 4. Accumulation of (−)-[11C]galanthamine in rat brain sections as determined by in 
vitro autoradiography, with: AChE staining of a rat coronal brain section (a); representative 
in vitro autoradiograms of rat coronal brain sections at 30 min after incubation of (−)-
[11C]galanthamine (b), with galanthamine (10 mM) (c), or donepezil (20 µM) (d); 
illustration of the significant decrease in accumulation of (−)-[11C]galanthamine in the 




Fig. 5. Sagittal PET image of (−)-[11C]galanthamine in the ddY 
mouse. The region surrounded by the ellipse indicates the 


























a: Tf2O, pyridine, 0 
oC, 91%, b: Pd(OAc)2, dppf, Et3N, HCO2H, DMF, 60 
oC, 97%, c: NaOH, MeOH, rt, 98%, d: L-Selectride, THF, −78 
oC to rt, 84%, e: (method A) HCHO, NaBH3CN, CH3CO2H, rt, 5 min, 92%,  (method B) CH3OTf, Cs2CO3, DMSO, 170 
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+(−)-6  or   (+)-6
Table 1. 
Table 1.  AChE inhibitory activit ies  of  ( − ) -  and (+) - galanthamine.   
    Inhibition (%)  
(–) - galanthamine   94  ± 2.7   
(+) - galanthamine   10 ± 4.4   
galanthamine  .   .HBr   from  Lycoris  sp.  95 ± 1.0   
n = 3.     
